Fixing vascular leak in IL-2 immunotherapy

Neither of the two marketed IL-2 immunotherapies for cancer is widely used due to potentially severe side effects such as vascular leak syndrome. Now, Swiss researchers have shown that lung endothelial cells magnify IL-2's toxicity. They have gone on to develop cytokine-antibody complexes that uncouple the efficacy of IL-2 therapeutics from their side effects by reducing IL-2 receptor activation on these cells.¹

Nascent Biologics Inc. has licensed the work and is humanizing the mAb component of the compounds...